As part of Invitae's network, patients can build datasets tracking their experiences with rare conditions and make the deidentified data available for research.
Under the collaboration, Invitae will gain access to Kew's 435-gene tumor profiling NGS panel and proprietary bioinformatics software.
The loan can be funded at Invitae's option during the second quarter of 2018 and will provide flexibility as the firm grows its genome network.
Invitae reported $25.4 million in fourth quarter revenues compared to $9.2 million in Q4 2016, beating the consensus Wall Street estimate.
The Index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, and reversed the 3 percent loss it saw in December.
At the Precision Medicine World Conference, Invitae executives noted that early experience in the genetic screening pilot found more people received positive results than previously expected.
Among the firms reporting, BGI talked about plans to cut down the time and cost of its WGS service, and Invitae's CEO made a surprising proclamation about genetic testing.
Invitae is expecting to net revenues of $59 million in 2017 via its base business, and $67 million in total revenues including acquired companies.
The company will now offer free genetic testing to patients at risk for acute hepatic porphyrias, a class of diseases for which it is developing a treatment.
GenScript believes that CustomArray's oligonucleotide synthesis and microarray manufacturing technology will enable it to better serve its customers.
A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.
A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.
NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.
In Nature this week: epigenetic factors that prevent healthy aging and more.